ADHD Drug CTx-1301 Receives Complete Response Letter

By
Kathryn Wighton
June 2, 2026

Conexiant

Overview

The FDA issued a Complete Response Letter for CTx-1301, an investigational dexmethylphenidate hydrochloride treatment for ADHD. The letter focused on Chemistry, Manufacturing, and Controls requests without raising concerns about clinical safety or efficacy.

Background

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder that significantly impacts daily functioning. Effective pharmacotherapy is crucial for managing symptoms, and new treatment options are continually being explored. CTx-1301 represents a novel approach in ADHD treatment with its multi-core tablet design aimed at providing timed releases of medication throughout the day. It remains investigational and is not approved by the FDA.

Data Highlights

No numerical data available in the source material.

Key Findings

The FDA's Complete Response Letter for CTx-1301 was limited to Chemistry, Manufacturing, and Controls requests.
No current concerns regarding clinical safety or efficacy of CTx-1301 were identified by the FDA.
CTx-1301 is designed as a once-daily, multi-core tablet for ADHD treatment.
The product is being evaluated under the FDA’s 505(b)(2) pathway.
The NDA for CTx-1301 was accepted for review in October 2025, with a target action date of May 31, 2026.

Clinical Implications

Healthcare professionals should remain informed about the status of investigational ADHD treatments like CTx-1301. The absence of safety or efficacy concerns in the FDA's feedback may support future clinical use pending successful resolution of CMC issues. Note that CTx-1301 remains investigational and is not FDA-approved.

Conclusion

CTx-1301's development continues to progress despite the recent FDA letter, highlighting the importance of addressing manufacturing concerns in the pathway to approval. It is crucial to remember that CTx-1301 is still investigational and not yet approved.